Greek parliament OKs bill on drug pricing, despite opposition protests

29 November 2013
lots-of-pills-big

Despite objections of the major opposition Coalition of the Radical Left (SYRIZA) party that critics said wanted to protect profits for big pharmaceutical companies who provide it financial support, the Greek Parliament has approved cuts in the prices of state-subsidized medicines, according to the Greek Reporter.

The legislation put forward by Health Minister Adonis Georgiadis - which foresees the reduction of prices in some 6,000 drugs - won easily, by a vote of 164-72 with 10 abstentions. The measure got the backing of all 154 members from the ruling party of New Democracy Conservative leader and Prime Minister Antonis Samaras and his coalition partner, the PASOK Socialists, along with the other 10 votes from independent and Democratic Left (DIMAR) deputies.

SFEE fears drug shortages

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical